德視佳(01846.HK)年度純利跌37.3%至8228.5萬港元 末期息0.0297港元
格隆匯3月31日丨德視佳(01846.HK)公佈年度業績,截至2024年12月31日止年度,公司收益爲7.16億港元,同比增長0.2%;公司擁有人應佔溢利爲8228.5萬港元,同比減少37.3%,每股基本盈利24.929港仙,擬派末期息每股普通股0.0297港元。
公告稱,集團自上市以來連續第六次實現收益增長,2024年度收益達7.16億港元,較2023年的7.14億港元再創歷史新高。晶體置換手術分部是上述增長的主要動力,在年內面對重重挑戰之際仍同比增長5.1%至3.91億港元。對這種老花眼治療方法的強勁需求亦推動了集團在德國、英國及中國三大市場的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.